APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Coagulation Factor Ⅷ for Injection

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Recombinant Coagulation Factor Ⅷ for Injection Market Analysis and Forecast 2026-2032

31 December 2025198 pages

Choose your research edition.

Industry ResearchRecombinant Coagulation Factor Ⅷ for Injection Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Coagulation Factor Ⅷ for Injection Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Recombinant Coagulation Factor Ⅷ for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Coagulation Factor Ⅷ for Injection Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Coagulation Factor Ⅷ for Injection Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Recombinant Coagulation Factor Ⅷ for Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Recombinant Coagulation Factor Ⅷ for Injection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Recombinant Coagulation Factor Ⅷ for Injection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Recombinant Coagulation Factor Ⅷ for Injection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Recombinant Coagulation Factor Ⅷ for Injection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Recombinant Coagulation Factor Ⅷ for Injection include GC Pharma, Novo Nordisk A/S, SinoCell Tech, Baxter, Bayer, Hualan Biological, Pfizer, Shanghai Raas Corp and Shanghai Xinxing Medicine, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Recombinant Coagulation Factor Ⅷ for Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Recombinant Coagulation Factor Ⅷ for Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Recombinant Coagulation Factor Ⅷ for Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Recombinant Coagulation Factor Ⅷ for Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Recombinant Coagulation Factor Ⅷ for Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Recombinant Coagulation Factor Ⅷ for Injection sales, projected growth trends, production technology, application and end-user industry.

Recombinant Coagulation Factor Ⅷ for Injection Segment by Company

GC Pharma

Novo Nordisk A/S

SinoCell Tech

Baxter

Bayer

Hualan Biological

Pfizer

Shanghai Raas Corp

Shanghai Xinxing Medicine

Shandong Taibang Biological Products

Recombinant Coagulation Factor Ⅷ for Injection Segment by Type

250 IU/Bottle

500 IU/Bottle

1000 IU/Bottle

2000 IU/Bottle

Recombinant Coagulation Factor Ⅷ for Injection Segment by Application

Hospital

Clinic

Others

Recombinant Coagulation Factor Ⅷ for Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Coagulation Factor Ⅷ for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Coagulation Factor Ⅷ for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Coagulation Factor Ⅷ for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Recombinant Coagulation Factor Ⅷ for Injection in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Recombinant Coagulation Factor Ⅷ for Injection manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Coagulation Factor Ⅷ for Injection sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Recombinant Coagulation Factor Ⅷ for Injection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 250 IU/Bottle Major Manufacturers Table 3. 500 IU/Bottle Major Manufacturers Table 4. 1000 IU/Bottle Major Manufacturers Table 5. 2000 IU/Bottle Major Manufacturers Table 6. Global Recombinant Coagulation Factor Ⅷ for Injection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Others Major Manufacturers Table 10. Recombinant Coagulation Factor Ⅷ for Injection Industry Trends Table 11. Recombinant Coagulation Factor Ⅷ for Injection Industry Drivers Table 12. Recombinant Coagulation Factor Ⅷ for Injection Industry Opportunities and Challenges Table 13. Recombinant Coagulation Factor Ⅷ for Injection Industry Restraints Table 14. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region (2021-2026) Table 18. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region (2027-2032) Table 19. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Units) Table 20. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2021-2026) & (Units) Table 21. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2027-2032) & (Units) Table 22. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Region (2021-2026) Table 23. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Region (2027-2032) Table 24. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Manufacturers (2021-2026) Table 28. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Recombinant Coagulation Factor Ⅷ for Injection Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Recombinant Coagulation Factor Ⅷ for Injection Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers, Product Type & Application Table 32. Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Recombinant Coagulation Factor Ⅷ for Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2021-2026) Table 39. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2027-2032) Table 40. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type 2021 VS 2025 VS 2032 (Units) Table 41. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2026) & (Units) Table 42. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2027-2032) & (Units) Table 43. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2021-2026) Table 44. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2027-2032) Table 45. Global Recombinant Coagulation Factor Ⅷ for Injection Price by Type (2021-2026) & (US$/Unit) Table 46. Global Recombinant Coagulation Factor Ⅷ for Injection Price by Type (2027-2032) & (US$/Unit) Table 47. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2021-2026) Table 51. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2027-2032) Table 52. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application 2021 VS 2025 VS 2032 (Units) Table 53. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2026) & (Units) Table 54. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2027-2032) & (Units) Table 55. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2021-2026) Table 56. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2027-2032) Table 57. Global Recombinant Coagulation Factor Ⅷ for Injection Price by Application (2021-2026) & (US$/Unit) Table 58. Global Recombinant Coagulation Factor Ⅷ for Injection Price by Application (2027-2032) & (US$/Unit) Table 59. GC Pharma Company Information Table 60. GC Pharma Business Overview Table 61. GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 63. GC Pharma Recent Development Table 64. Novo Nordisk A/S Company Information Table 65. Novo Nordisk A/S Business Overview Table 66. Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 68. Novo Nordisk A/S Recent Development Table 69. SinoCell Tech Company Information Table 70. SinoCell Tech Business Overview Table 71. SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 73. SinoCell Tech Recent Development Table 74. Baxter Company Information Table 75. Baxter Business Overview Table 76. Baxter Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Baxter Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 78. Baxter Recent Development Table 79. Bayer Company Information Table 80. Bayer Business Overview Table 81. Bayer Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Bayer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 83. Bayer Recent Development Table 84. Hualan Biological Company Information Table 85. Hualan Biological Business Overview Table 86. Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 88. Hualan Biological Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Pfizer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 93. Pfizer Recent Development Table 94. Shanghai Raas Corp Company Information Table 95. Shanghai Raas Corp Business Overview Table 96. Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 98. Shanghai Raas Corp Recent Development Table 99. Shanghai Xinxing Medicine Company Information Table 100. Shanghai Xinxing Medicine Business Overview Table 101. Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 103. Shanghai Xinxing Medicine Recent Development Table 104. Shandong Taibang Biological Products Company Information Table 105. Shandong Taibang Biological Products Business Overview Table 106. Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 108. Shandong Taibang Biological Products Recent Development Table 109. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2026) & (US$ Million) Table 110. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2027-2032) & (US$ Million) Table 111. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2026) & (Units) Table 112. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2027-2032) & (Units) Table 113. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 114. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 115. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2026) & (US$ Million) Table 116. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2027-2032) & (US$ Million) Table 117. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2026) & (Units) Table 118. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2027-2032) & (Units) Table 119. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 120. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 121. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 123. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 124. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 125. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 126. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 127. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Country (2021-2026) & (US$/Unit) Table 128. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Country (2027-2032) & (US$/Unit) Table 129. United States Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 130. Canada Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 131. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2026) & (US$ Million) Table 132. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2027-2032) & (US$ Million) Table 133. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2026) & (Units) Table 134. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2027-2032) & (Units) Table 135. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 136. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 137. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2026) & (US$ Million) Table 138. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2027-2032) & (US$ Million) Table 139. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2026) & (Units) Table 140. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2027-2032) & (Units) Table 141. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 142. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 143. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 145. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 146. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 147. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 148. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 149. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Country (2021-2026) & (US$/Unit) Table 150. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Country (2027-2032) & (US$/Unit) Table 151. Germany Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 152. France Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 153. U.K. Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 154. Italy Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 155. Netherlands Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 156. Nordic Countries Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 157. China Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2026) & (US$ Million) Table 158. China Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2027-2032) & (US$ Million) Table 159. China Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2026) & (Units) Table 160. China Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2027-2032) & (Units) Table 161. China Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 162. China Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 163. China Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2026) & (US$ Million) Table 164. China Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2027-2032) & (US$ Million) Table 165. China Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2026) & (Units) Table 166. China Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2027-2032) & (Units) Table 167. China Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 168. China Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 169. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2026) & (US$ Million) Table 170. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2027-2032) & (US$ Million) Table 171. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2026) & (Units) Table 172. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2027-2032) & (Units) Table 173. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 174. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 175. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2026) & (US$ Million) Table 176. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2027-2032) & (US$ Million) Table 177. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2026) & (Units) Table 178. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2027-2032) & (Units) Table 179. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 180. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 181. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 182. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 183. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 184. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 185. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 186. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 187. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Country (2021-2026) & (US$/Unit) Table 188. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Country (2027-2032) & (US$/Unit) Table 189. Japan Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 190. South Korea Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 191. India Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 192. Australia Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 193. China Taiwan Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 194. Southeast Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 195. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2026) & (US$ Million) Table 196. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2027-2032) & (US$ Million) Table 197. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2026) & (Units) Table 198. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2027-2032) & (Units) Table 199. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 200. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 201. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2026) & (US$ Million) Table 202. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2027-2032) & (US$ Million) Table 203. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2026) & (Units) Table 204. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2027-2032) & (Units) Table 205. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 206. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 207. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 208. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 209. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 210. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 211. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 212. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 213. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Country (2021-2026) & (US$/Unit) Table 214. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Country (2027-2032) & (US$/Unit) Table 215. Brazil Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 216. Argentina Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 217. Chile Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 218. Colombia Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 219. Peru Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 220. Saudi Arabia Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 221. Israel Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 222. UAE Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 223. Turkey Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 224. Iran Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 225. Egypt Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Table 226. Key Raw Materials Table 227. Raw Materials Key Suppliers Table 228. Recombinant Coagulation Factor Ⅷ for Injection Distributors List Table 229. Recombinant Coagulation Factor Ⅷ for Injection Customers List Table 230. Research Programs/Design for This Report Table 231. Authors List of This Report Table 232. Secondary Sources Table 233. Primary Sources List of Figures Figure 1. Recombinant Coagulation Factor Ⅷ for Injection Image Figure 2. Global Recombinant Coagulation Factor Ⅷ for Injection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Coagulation Factor Ⅷ for Injection Market Size Share 2021 VS 2025 VS 2032 Figure 4. 250 IU/Bottle Image Figure 5. 500 IU/Bottle Image Figure 6. 1000 IU/Bottle Image Figure 7. 2000 IU/Bottle Image Figure 8. Global Recombinant Coagulation Factor Ⅷ for Injection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Recombinant Coagulation Factor Ⅷ for Injection Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Figure 15. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region (2021-2032) Figure 18. Global Recombinant Coagulation Factor Ⅷ for Injection Sales (2021-2032) & (Units) Figure 19. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 20. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Recombinant Coagulation Factor Ⅷ for Injection Sales YoY (2021-2032) & (Units) Figure 22. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales YoY (2021-2032) & (Units) Figure 23. China Recombinant Coagulation Factor Ⅷ for Injection Sales YoY (2021-2032) & (Units) Figure 24. Asia (Excluding China) Recombinant Coagulation Factor Ⅷ for Injection Sales YoY (2021-2032) & (Units) Figure 25. South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales YoY (2021-2032) & (Units) Figure 26. Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2021-2032) Figure 32. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 33. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2021-2032) Figure 35. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2021-2032) Figure 38. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 39. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2021-2032) Figure 41. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Type (2021-2032) Figure 42. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Type (2021-2032) Figure 43. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Application (2021-2032) Figure 44. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Application (2021-2032) Figure 45. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country (2021-2032) Figure 46. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Country (2021-2032) Figure 47. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Type (2021-2032) Figure 48. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Type (2021-2032) Figure 49. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Application (2021-2032) Figure 50. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Application (2021-2032) Figure 51. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country (2021-2032) Figure 52. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Country (2021-2032) Figure 53. China Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Type (2021-2032) Figure 54. China Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Type (2021-2032) Figure 55. China Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Application (2021-2032) Figure 56. China Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Application (2021-2032) Figure 57. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Type (2021-2032) Figure 58. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Type (2021-2032) Figure 59. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Application (2021-2032) Figure 60. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Application (2021-2032) Figure 61. Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country (2021-2032) Figure 62. Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Country (2021-2032) Figure 63. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Type (2021-2032) Figure 64. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Type (2021-2032) Figure 65. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Application (2021-2032) Figure 66. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Application (2021-2032) Figure 67. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country (2021-2032) Figure 68. SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales Share by Country (2021-2032) Figure 69. Recombinant Coagulation Factor Ⅷ for Injection Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Recombinant Coagulation Factor Ⅷ for Injection Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • 250 IU/Bottle
  • 500 IU/Bottle
  • 1000 IU/Bottle
  • 2000 IU/Bottle
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • GC Pharma
  • Novo Nordisk A/S
  • SinoCell Tech
  • Baxter
  • Bayer
  • Hualan Biological
  • Pfizer
  • Shanghai Raas Corp
  • Shanghai Xinxing Medicine
  • Shandong Taibang Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Recombinant Coagulation Factor Ⅷ for Injection Market by Type
  3. 1.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 250 IU/Bottle
  5. 1.2.3 500 IU/Bottle
  6. 1.2.4 1000 IU/Bottle
  7. 1.2.5 2000 IU/Bottle
  8. 1.3 Recombinant Coagulation Factor Ⅷ for Injection Market by Application
  9. 1.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Recombinant Coagulation Factor Ⅷ for Injection Market Dynamics
  1. 2.1 Recombinant Coagulation Factor Ⅷ for Injection Industry Trends
  2. 2.2 Recombinant Coagulation Factor Ⅷ for Injection Industry Drivers
  3. 2.3 Recombinant Coagulation Factor Ⅷ for Injection Industry Opportunities and Challenges
  4. 2.4 Recombinant Coagulation Factor Ⅷ for Injection Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region
  3. 3.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2021-2026)
  5. 3.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2027-2032)
  6. 3.2.4 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region
  9. 3.4.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2021-2026)
  11. 3.4.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2027-2032)
  12. 3.4.4 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Manufacturers
  2. 4.1.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Manufacturers
  6. 4.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Recombinant Coagulation Factor Ⅷ for Injection Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Recombinant Coagulation Factor Ⅷ for Injection Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers, Product Type & Application
  13. 4.7 Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market CR5 and HHI
  16. 4.8.2 2025 Recombinant Coagulation Factor Ⅷ for Injection Tier 1, Tier 2, and Tier 3
5 Recombinant Coagulation Factor Ⅷ for Injection Market by Type
  1. 5.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type
  2. 5.1.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type
  6. 5.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032) & (Units)
  8. 5.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2021-2032)
  9. 5.3 Global Recombinant Coagulation Factor Ⅷ for Injection Price by Type
6 Recombinant Coagulation Factor Ⅷ for Injection Market by Application
  1. 6.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application
  2. 6.1.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application
  6. 6.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032) & (Units)
  8. 6.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2021-2032)
  9. 6.3 Global Recombinant Coagulation Factor Ⅷ for Injection Price by Application
7 Company Profiles
  1. 7.1 GC Pharma
  2. 7.1.1 GC Pharma Company Information
  3. 7.1.2 GC Pharma Business Overview
  4. 7.1.3 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  6. 7.1.5 GC Pharma Recent Developments
  7. 7.2 Novo Nordisk A/S
  8. 7.2.1 Novo Nordisk A/S Company Information
  9. 7.2.2 Novo Nordisk A/S Business Overview
  10. 7.2.3 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  12. 7.2.5 Novo Nordisk A/S Recent Developments
  13. 7.3 SinoCell Tech
  14. 7.3.1 SinoCell Tech Company Information
  15. 7.3.2 SinoCell Tech Business Overview
  16. 7.3.3 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  18. 7.3.5 SinoCell Tech Recent Developments
  19. 7.4 Baxter
  20. 7.4.1 Baxter Company Information
  21. 7.4.2 Baxter Business Overview
  22. 7.4.3 Baxter Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Baxter Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  24. 7.4.5 Baxter Recent Developments
  25. 7.5 Bayer
  26. 7.5.1 Bayer Company Information
  27. 7.5.2 Bayer Business Overview
  28. 7.5.3 Bayer Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bayer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  30. 7.5.5 Bayer Recent Developments
  31. 7.6 Hualan Biological
  32. 7.6.1 Hualan Biological Company Information
  33. 7.6.2 Hualan Biological Business Overview
  34. 7.6.3 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  36. 7.6.5 Hualan Biological Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Shanghai Raas Corp
  44. 7.8.1 Shanghai Raas Corp Company Information
  45. 7.8.2 Shanghai Raas Corp Business Overview
  46. 7.8.3 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  48. 7.8.5 Shanghai Raas Corp Recent Developments
  49. 7.9 Shanghai Xinxing Medicine
  50. 7.9.1 Shanghai Xinxing Medicine Company Information
  51. 7.9.2 Shanghai Xinxing Medicine Business Overview
  52. 7.9.3 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  54. 7.9.5 Shanghai Xinxing Medicine Recent Developments
  55. 7.10 Shandong Taibang Biological Products
  56. 7.10.1 Shandong Taibang Biological Products Company Information
  57. 7.10.2 Shandong Taibang Biological Products Business Overview
  58. 7.10.3 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  60. 7.10.5 Shandong Taibang Biological Products Recent Developments
8 North America
  1. 8.1 North America Recombinant Coagulation Factor Ⅷ for Injection Market Size by Type
  2. 8.1.1 North America Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2032)
  3. 8.1.2 North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032)
  4. 8.1.3 North America Recombinant Coagulation Factor Ⅷ for Injection Price by Type (2021-2032)
  5. 8.2 North America Recombinant Coagulation Factor Ⅷ for Injection Market Size by Application
  6. 8.2.1 North America Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2032)
  7. 8.2.2 North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032)
  8. 8.2.3 North America Recombinant Coagulation Factor Ⅷ for Injection Price by Application (2021-2032)
  9. 8.3 North America Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country
  10. 8.3.1 North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Recombinant Coagulation Factor Ⅷ for Injection Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Market Size by Type
  2. 9.1.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2032)
  3. 9.1.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032)
  4. 9.1.3 Europe Recombinant Coagulation Factor Ⅷ for Injection Price by Type (2021-2032)
  5. 9.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Market Size by Application
  6. 9.2.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2032)
  7. 9.2.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032)
  8. 9.2.3 Europe Recombinant Coagulation Factor Ⅷ for Injection Price by Application (2021-2032)
  9. 9.3 Europe Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country
  10. 9.3.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Recombinant Coagulation Factor Ⅷ for Injection Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Recombinant Coagulation Factor Ⅷ for Injection Market Size by Type
  2. 10.1.1 China Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2032)
  3. 10.1.2 China Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032)
  4. 10.1.3 China Recombinant Coagulation Factor Ⅷ for Injection Price by Type (2021-2032)
  5. 10.2 China Recombinant Coagulation Factor Ⅷ for Injection Market Size by Application
  6. 10.2.1 China Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2032)
  7. 10.2.2 China Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032)
  8. 10.2.3 China Recombinant Coagulation Factor Ⅷ for Injection Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Recombinant Coagulation Factor Ⅷ for Injection Market Size by Type
  2. 11.1.1 Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2032)
  3. 11.1.2 Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032)
  4. 11.1.3 Asia Recombinant Coagulation Factor Ⅷ for Injection Price by Type (2021-2032)
  5. 11.2 Asia Recombinant Coagulation Factor Ⅷ for Injection Market Size by Application
  6. 11.2.1 Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2032)
  7. 11.2.2 Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032)
  8. 11.2.3 Asia Recombinant Coagulation Factor Ⅷ for Injection Price by Application (2021-2032)
  9. 11.3 Asia Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country
  10. 11.3.1 Asia Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Recombinant Coagulation Factor Ⅷ for Injection Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Market Size by Type
  2. 12.1.1 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Price by Type (2021-2032)
  5. 12.2 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Market Size by Application
  6. 12.2.1 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Price by Application (2021-2032)
  9. 12.3 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country
  10. 12.3.1 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Recombinant Coagulation Factor Ⅷ for Injection Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Recombinant Coagulation Factor Ⅷ for Injection Value Chain Analysis
  2. 13.1.1 Recombinant Coagulation Factor Ⅷ for Injection Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Recombinant Coagulation Factor Ⅷ for Injection Production Mode & Process
  6. 13.2 Recombinant Coagulation Factor Ⅷ for Injection Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Recombinant Coagulation Factor Ⅷ for Injection Distributors
  9. 13.2.3 Recombinant Coagulation Factor Ⅷ for Injection Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst